Bonjesta® Savings

Bonjesta® Savings Options

Option 1 - Mail Order Pharmacy

Bonjesta at Home® program
offers the lowest price regardless of coverage

If you have commercial insurance

Pay aslittle as
$ 40 *
perprescription

If your insurance does not cover Bonjesta®
or you do not have insurance:

Pay aslittle as
$ 99 *
perprescription

Ask your doctor to prescribe through
Bonjesta at Home® and receive:

  • Free Home delivery
  • On-staff pharmacists to answer product questions
  • Assistance with insurance benefit verification
  • Monthly refill reminders

Questions? Call (844) 716-HOME (4663)

*see terms and conditions

3 Easy Ways for Healthcare Professionals to Prescribe through the Bonjesta at Home® program:

  1. ePrescribe: NCPDP 3685508; NPI 1487163598
  2. Fax form from hcp.Bonjesta.com to (800) 949-3434 or email [email protected]
  3. Call (844) 716-HOME (4663)

Available only through: PhilRx, 150 E Campus View Blvd, Ste 210 Columbus, OH 43235

Option 2 - Retail Pharmacy

Bonjesta® Savings Cards

If you have commercial insurance

Pay aslittle as
$ 40 *
perprescription

Questions? Call (347) 657-9766

Apollo Care Processing Information:

  • Bin: 610020
  • Group ID: 99995052
  • RxPCN: ACR
  • ID#: 26512200301

If your insurance does not cover Bonjesta®
or you do not have insurance:

good-rx logo
Good
Rx
Savings Offer

Pay as
little as

  • $3.32 / tablet* for 60 or more tablets**
  • $199* for 60 tablets

GoodRx Processing Information:

  • Bin: 610020
  • Group ID: 99995427
  • RxPCN: PDM
  • ID#: ERXBONJESTA
GoodRx is NOT insurance. Cancel anytime. By continuing, you agree to the GoodRx Terms of Use and Privacy Policy available at goodrx.com/terms. © 2025 GoodRx, Inc., 2701 Olympic Blvd., Santa Monica, CA 90404
*See terms and conditions
**Price per tablet may vary for quantities less than 60 tablets.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

BONJESTA® is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

LIMITATIONS OF USE

BONJESTA® has not been studied in women with hyperemesis gravidarum.

IMPORTANT SAFETY INFORMATION

Contraindications:

BONJESTA® is contraindicated in women with any of the following conditions:

  • Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation;
  • Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of BONJESTA®.

Warnings and Precautions:

  • Somnolence: BONJESTA® may cause somnolence due to the anticholinergic properties of doxylamine succinate, an antihistamine. Women should avoid engaging in activities requiring complete mental alertness, such as driving or operating heavy machinery, while using BONJESTA® until cleared to do so by their healthcare provider.
  • Central nervous system (CNS) depressants: Use of BONJESTA® is not recommended if a woman is concurrently using CNS depressants, such as alcohol or sedating medications, including other antihistamines (present in some cough and cold medications), opiates, and sleep aids. The combination of BONJESTA® and CNS depressants could result in severe drowsiness leading to falls or other accidents.
  • Concomitant Medical Conditions: BONJESTA® has anticholinergic properties and, therefore, should be used with caution in women with increased intraocular pressure, narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, or bladder-neck obstruction.
  • Interference with Urine Screen for Methadone, Opiates and Phencyclidine Phosphate (PCP): There have been reports of false positive urine screening tests for methadone, opiates, and PCP with doxylamine succinate/pyridoxine hydrochloride use. Women should be informed that use of BONJESTA® may result in false positive urine drug screening for methadone, opiates, and PCP.

Adverse Reactions:

The most common adverse reaction (≥5 percent and exceeding the rate in placebo) is somnolence.

Drug-Food Interactions:

BONJESTA® should be taken on an empty stomach with a glass of water.

Drug Interactions:

Severe drowsiness can occur when used in combination with alcohol or other sedating medications.

Use in Specific Populations:

  • Pregnancy: BONJESTA® is intended for use in pregnant women.
  • Lactation: Women should not breastfeed while using BONJESTA® because the antihistamine component (doxylamine succinate) in BONJESTA® can pass into breast milk. Excitement, irritability, and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. Infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of BONJESTA®, resulting in worsening of their apnea or respiratory conditions.
  • Pediatric Use: The safety and effectiveness of BONJESTA® in children under 18 years of age have not been established. Fatalities have been reported from doxylamine overdose in children. Children appear to be at a high risk for cardiorespiratory arrest.

Overdosage:

BONJESTA® is an extended-release formulation; therefore, signs and symptoms of intoxication may not be apparent immediately. Signs and symptoms of overdose may include restlessness, dryness of mouth, dilated pupils, sleepiness, vertigo, mental confusion, and tachycardia. At toxic doses, doxylamine exhibits anticholinergic effects, including seizures, rhabdomyolysis, acute renal failure, and death. If treatment is needed, it consists of gastric lavage or activated charcoal, whole bowel irrigation, and symptomatic treatment. If you suspect an overdose or seek additional information about overdose treatment, call a poison control center at 1-800-222-1222.

To report suspected adverse reactions, contact Duchesnay Inc. at 1-855-722-7734 or [email protected] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This site is intended for U.S. healthcare professionals only Medical practices, products and/or regulations may be different from one country to another. As a result, the medical and/or product information on this site is not intended for use outside of the United States. The information is not meant to suggest any medical course of action. Rather, it is intended to inform and to raise awareness so that these issues can be discussed with qualified healthcare providers.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

BONJESTA® is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.

LIMITATIONS OF USE

BONJESTA® has not been studied in women with hyperemesis gravidarum.